Sophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at AUA
Tweet Send to a Friend
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) as a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
